Saller R, Hellenbrecht D, Hellstern A, Hess H
Eur J Clin Pharmacol. 1985;29(3):311-2. doi: 10.1007/BF00544086.
Metoclopramide (Paspertin) was infused intravenously in the high doses of 1.75, 3.5, 7.0, and 14 mg/kg body wt. per treatment cycle as antiemetic therapy for cisplatin-induced emesis (363 cycles, 25-120 mg/m2). The antiemetic potency of metoclopramide increased in a log linear manner, giving from 40% to 95% protection against emesis. Gastrointestinal motility showed a similar increase, i.e. diarrhoea. In contrast, the extrapyramidal reactions, namely akathisia, rigidity and acute dystonia, did not show a dose-dependent increase in frequency and remained constant over the dose range of 3.5-14 mg/kg per cycle. The results suggest increasing benefit of metoclopramide treatment with increasing doses of the drug.
甲氧氯普胺（胃复安）以每治疗周期1.75、3.5、7.0和14毫克/千克体重的高剂量静脉输注，作为顺铂诱导呕吐（363个周期，25 - 120毫克/平方米）的止吐疗法。甲氧氯普胺的止吐效力呈对数线性增加，对呕吐的防护率从40%提高到95%。胃肠动力也有类似增加，即腹泻。相比之下，锥体外系反应，即静坐不能、僵硬和急性肌张力障碍，其发生频率并未呈剂量依赖性增加，在每周期3.5 - 14毫克/千克的剂量范围内保持恒定。结果表明，随着药物剂量增加，甲氧氯普胺治疗的益处也增加。
